Dare Bioscience (DARE) Reports Q3 Loss of $0.23

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. DOX
4. AMGN
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Dare Bioscience (DARE) Reports Q3 Loss of $0.23

Daré Bioscience Provides Business Update and Announces Third Quarter Financial Results

November 13, 2018 7:30 AM EST

SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, womens biopharmaceutical company, today provided a business update and announced financial results for the three and nine months ended September 30, 2018.

Business Update

We are actively enrolling couples in our postcoital test clinical trial of Ovaprene®, our non-hormonal monthly contraceptive, and are preparing to commence the Phase2b program of Sildenafil Cream, 3.6%, our candidate for the treatment of female sexual arousal disorder. We are also advancing our development portfolio of other... More